Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Co-Diagnostics (CODX) Misses Q3 EPS by 10c, Revenues Miss
November 16, 2020 4:07 PM ESTCo-Diagnostics (NASDAQ: CODX) reported Q3 EPS of $0.53, $0.10 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $21.82 million versus the consensus estimate of $32.79 million.
Q3 2020 Highlights:
Company continues COVID-19 test sales and reports $21.8 million of revenue in Q3;Quarterly net income of $15.7 million and net income per diluted common share of $0.53;Year-to-date net income of $29.7 million and $1.07 per... More